Summary

U.S. Dupixent Market Summary

The U.S. dupixent market size was estimated at USD 10.39 billion in 2024 and is projected to reach USD 16.82 billion by 2033, growing at a CAGR of 5.47% from 2025 to 2033. The market growth dominates due to high healthcare access in the U.S.

The U.S. dupixent industry is driven by the rising prevalence of chronic inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent FDA approval for chronic obstructive pulmonary disease (COPD) in September 2024, particularly in adolescent patients, has expanded the drug’s therapeutic scope.

Dupixent, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, addresses unmet clinical needs in moderate-to-severe inflammatory diseases. Its demonstrated efficacy in atopic dermatitis and severe asthma has positioned it as a leading biologic in the U.S. market.

Healthcare infrastructure and expenditure trends support the drug’s adoption. The U.S. recorded USD 4.9 trillion in healthcare spending in 2023, driven by increasing biologic uptake and demand for specialty care. However, 26 million uninsured Americans and reimbursement gaps remain a constraint on market reach. Despite these limitations, telehealth adoption, utilized by 20% of patients, has improved access in urban settings. In contrast, rural areas, which account for 19% of the population, continue to face access limitations.

The aging population, with 58 million Americans over the age of 65, is contributing to rising COPD prevalence, further supporting demand. In addition, the annual 2% rise in atopic dermatitis and asthma cases, largely due to environmental factors, reinforces market growth.

Dupixent’s subcutaneous administration and favorable safety profile compared to corticosteroids improve patient compliance. Real-world evidence studies, backed by Sanofi and the market, are supported by emerging pipeline innovations such as eosinophilic esophagitis, optimized dosing regimens, and expanded manufacturing capacity. However, high treatment costs and coverage limitations in underserved regions pose challenges. Strategic collaborations and patient assistance programs are being implemented to address these barriers, sustaining growth momentum through 2033.

U.S. Dupixent Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. dupixent market report based on indication and distribution channel:

• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Atopic Dermatitis (AD)
• Asthma
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
• Chronic Obstructive Pulmonary Disease (COPD)
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Dupixent Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. U.S. Dupixent Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
4.4. Atopic Dermatitis (AD)
4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Billion)
4.5. Asthma
4.5.1. Asthma Market, 2021 - 2033 (USD Billion)
4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Billion)
4.7. Chronic Obstructive Pulmonary Disease (COPD)
4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Billion)
4.8. Others
4.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Dupixent Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
5.6. Others
5.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
6.5.1. Sanofi
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Regeneron
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives